ArticleScientific reports2025
Autologous serum supplementation promotes the phenotype maintenance of human chondrocytes with increased cellular autophagy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Arthroscopically and manually minced cartilage demonstrates lower cell viability and lower proteoglycan deposition compared to isolated chondrons and chondrocytes.Osteoarthritis and cartilage open · 2026Article
- The Effect of Physical, Biochemical, and Electrical Culture Conditions on Articular Chondrocytes Used for Cartilage Tissue Engineering: A Narrative Review.International journal of molecular sciences · 2026Review
- Evaluation of Cartilage Repair After Implantation of Labeled Human Chondrocytes as Free Cells or Spheroids in Rabbit Knees.International journal of molecular sciences · 2026Article
- Autologous Serum and Non-Cultured Epidermal Cell Suspension for Stable Vitiligo: A 30-Patient Case Series.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Articular cartilage lacks the capacity for self-repair after injury, rendering autologous chondrocyte transplantation a crucial treatment option for severe cartilage damage. However, the in vitro expansion of chondrocytes in elderly patients poses challenges, particularly due to inadequate cell numbers and rapid phenotypic loss, often exacerbated by the use of animal-derived serum. In this study, we propose the utilization of human autologous serum (HAS) as a supplement in the in vitro cell culture to preserve the phenotype of chondrocytes isolated from the same patient. Chondrocytes cultured in medium supplemented with 5% HAS demonstrated improved cell proliferation and adherence, whereas a 10% concentration promoted a more differentiated phenotype. While 10% fetal bovine serum stimulates chondrocyte proliferation in the short term, 10% HAS is more advantageous for the long-term viability of cells. Notably, chondrocytes treated with the optimal 10% HAS supplementation exhibited a higher level of autophagy compared to those treated with 5% HAS alone. Our findings suggest that 10% human autologous serum holds promise for the efficient expansion of patient-derived autologous chondrocytes and facilitates the maintenance of chondrocyte phenotype, in part through enhanced cellular autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.